Longboard Pharmaceuticals, Inc. (LBPH)
USD 59.98
(0.0%)
USD 59.98
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 5000.00 | 5000.00 | 1000.00 | - |
| Gross Profit | -5000.00 | -5000.00 | -1000.00 | - |
| Operating Expenses | 56.75 Million | 44.79 Million | 27.83 Million | 14.4 Million |
| Selling, General and Administrative Expenses | 13 Million | 10.16 Million | 8.06 Million | 9.76 Million |
| Research and Development Expenses | 43.75 Million | 34.63 Million | 19.77 Million | 4.63 Million |
| Other Expenses | - | 16 Thousand | -22 Thousand | - |
| Cost and Expenses | 56.75 Million | 44.79 Million | 27.83 Million | 14.4 Million |
| Operating Income | -56.75 Million | -44.79 Million | -27.83 Million | -14.4 Million |
| Interest Expense | - | 837 Thousand | - | - |
| Income Tax Expense | - | -853 Thousand | -64 Thousand | -14.4 Thousand |
| Earnings before Tax | -54.42 Million | -43.94 Million | -27.79 Million | -14.4 Million |
| Net Income | -54.42 Million | -43.09 Million | -27.73 Million | -14.4 Million |
| Earnings Per Share Basic | -2.39 | -2.51 | -1.62 | -0.82 |
| Earnings Per Share Diluted | -2.39 | -2.51 | -1.62 | -0.82 |
| Weighted Average Shares Outstanding | 22.72 Million | 17.15 Million | 17.07 Million | 17.66 Million |
| Weighted Average Shares Outstanding (Diluted) | 22.72 Million | 17.15 Million | 17.07 Million | 17.66 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -56.75 Million | -44.79 Million | -27.83 Million | -14.4 Million |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 8000.00 | - | - |
| Cost of Revenue | 2000.00 | 1000.00 | 5000.00 | 1000.00 | 1000.00 | 2000.00 |
| Gross Profit | -2000.00 | -1000.00 | -5000.00 | 7000.00 | -1000.00 | -2000.00 |
| Operating Expenses | 25.64 Million | 18.1 Million | 56.75 Million | 15.57 Million | 13.58 Million | 15.64 Million |
| Selling, General and Administrative Expenses | 5.19 Million | 4.93 Million | - | 3.37 Million | 3.09 Million | 3.1 Million |
| Research and Development Expenses | 20.44 Million | 13.17 Million | - | 12.19 Million | 10.48 Million | 12.53 Million |
| Other Expenses | -47 Thousand | -9000.00 | - | -27 Thousand | -14 Thousand | -17 Thousand |
| Cost and Expenses | 25.64 Million | 18.11 Million | 56.75 Million | 15.57 Million | 13.58 Million | 15.64 Million |
| Operating Income | -25.64 Million | -18.11 Million | -56.75 Million | -15.57 Million | -13.58 Million | -15.64 Million |
| Interest Expense | - | - | - | 506 Thousand | - | - |
| Income Tax Expense | -2000.00 | -42.27 Thousand | - | -567 Thousand | -1000.00 | -660 Thousand |
| Earnings before Tax | -21.78 Million | -14.98 Million | -54.42 Million | -15.03 Million | -12.93 Million | -14.99 Million |
| Net Income | -21.78 Million | -14.98 Million | -54.42 Million | -15.03 Million | -12.93 Million | -14.99 Million |
| Earnings Per Share Basic | -0.56 | -0.42 | - | -0.63 | -0.55 | -0.65 |
| Earnings Per Share Diluted | -0.56 | -0.42 | - | -0.63 | -0.55 | -0.65 |
| Weighted Average Shares Outstanding | 38.88 Million | 35.32 Million | 22.72 Million | 23.92 Million | 23.48 Million | 22.96 Million |
| Weighted Average Shares Outstanding (Diluted) | 38.88 Million | 35.32 Million | 22.72 Million | 23.92 Million | 23.48 Million | 22.96 Million |
| Gross Margin | - | - | - | 0.88 | - | - |
| EBIT Margin | - | - | - | -1946.50 | - | - |
| Profit Margin | - | - | - | -1879.12 | - | - |
| EBITDA | -25.64 Million | -18.1 Million | - | -15.57 Million | -13.58 Million | -15.64 Million |
| Earnings Before Tax Margin | - | - | - | -1946.62 | - | - |
6095
000540
PXPP
NODC
SRX
SBRANDS